Anti-Mouse CD4 [Clone GK1.5] F(ab’)2 Fragment — NIR-SHIELD™ (s775z)

Mouse CTL clone V4

This monoclonal antibody is aseptically packaged (0.2um filtered) and formulated in 0.01 M PBS (phosphate buffered saline) (150 mM NaCl) pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid repeated freeze thaw cycles.

Research Use Only

2-8°C

The ideal excitation is in the high‑700 nm range, with practical use on 750–775 nm lasers.

B
Costim
Depletion
IHC
IP

The emission maximum of the NIR-SHIELD (s775z) dye is published to be approximately 795 nm. This near-infrared dye has an excitation maximum around 775 nm and emits fluorescence maximally at 795 nm, making it suitable for fluorescence microscopy and in vivo imaging applications.

Rat Anti-Mouse CD4 antibody (Clone GK1.5) recognizes an epitope on Mouse CD4. This monoclonal CD4 antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

CD4 (cluster of differentiation 4) is a glycoprotein expressed on the surface of T helper cells, regulatory T cells, monocytes, macrophages, and dendritic cells. CD4 interacts with class II molecules of the major histocompatibility complex (MHC) enhancing the signal for T-cell activation.⁶

Majority of thymocytes, T cell subset

MHC class II molecule

T cell activation

1.) Ardolino, M. et al. (2018) J Clin Invest. 128(10):4654-4668. PubMed
2.) Schreiber, RD. et al. (2017) Cancer Immunol Res. 5(2):106-117. PubMed
3.) Nicolas, JF. et al. (2002) J Immunol.168(6):3079-87. Article Link
4.) Shin, H. et al. (2018) J Virol. 92(7): e00038-18. PubMed
5.) Chiang, BL. et al. (2001) Immunology. 2001 103(3): 301–309. PubMed
6.) Hendrickson, WA. et al. (1994) Structure 2: 59
7.) Skyberg, J. A. et al. (2020) Infection and Immunity. 88: 5 Journal Link
8.) Raju et al. (2019) Cell Reports. 29:2556–2564 Journal Link
9.) Gubin, M. et al. (2018) Cell. 175(4):1014–1030 Journal Link
10.) Sharma S. et al. (2020) Human Vaccines & Immunotherapeutics 16(9):2196-2203 Journal Link
11.) Hawman DW, et al. (2021) Microorganisms 9(2):279 Journal Link